Top Ten most popular articles on Pharmafile.com this week
October 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw …
2019 saw the FDA approve more generic drugs than ever before
October 18, 2019Medical Communications, Sales and Marketing FDA, US, generic drugs, pharma
Fiscal year 2019 was a record-breaking one, according to the FDA. The US regulator smashed its previous total for annual …
FDA panel gives positive vote for Shionogi’s Cefiderocol in Urinary Tract Infections
October 18, 2019Medical Communications
The US FDA has recommended approval for cefiderocol, a novel antibiotic for complicated urinary tract infections, including pyelonephritis, in patients …
FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza
October 18, 2019Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma
Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …
MSD to cut around 500 jobs in US next year
October 18, 2019Medical Communications
MSD have announced it plans to eliminate approximately 500 jobs in multiple US states according to a filing with the …
Drug manufacturers to settle US opioid litigation with $50 billion package
October 17, 2019Business Services
Five drug makers and distributors are now offering $22 billion in cash, as well as drugs and services, valued at …
UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis
October 17, 2019Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …
Ipsen acquires Blueprint drug and moves further into ultra-rare disease
October 17, 2019Research and Development
Ipsen has announced that through its subsidiary Clementia Pharmaceuticals, it has entered into an exclusive, worldwide license agreement for the …
Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
October 17, 2019Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
AstraZeneca receives FDA Priority Review for breast cancer drug
October 17, 2019Research and Development
AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription …
Gilead appoints Andrew Dickinson as CFO
October 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November. Dickinson currently …
Medical cannabis: Riding the wave
October 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma
Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …
Alexion to acquire Achillion Pharma for $930 million
October 16, 2019Research and Development, Sales and Marketing Alexion, achillion, merger, pharma
Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
China approves Eisai’s Fycompa for partial onset epileptic seizures
October 16, 2019Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma
Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
FDA approves first and only transdermal patch for schizophrenia
October 16, 2019Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia
Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …
Tranexamic acid to prevent brain bleeds could save thousands of lives
October 15, 2019Research and Development
A large controlled clinical trial has linked the early use of tranexamic acid to a small fall in the risk …
Takeda sheds 30 products in emerging markets in $200m deal
October 15, 2019Research and Development
Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa …
New UK Medicines Bill could improve access to new dementia treatments
October 15, 2019Manufacturing and Production
The Government has announced new legislation aimed at providing faster access to medicines, including those treating dementia and Alzheimer’s.The Medicines …
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
New £1.2m trial for Parkinson’s patients testing cannabidiol
October 15, 2019Manufacturing and Production
A new clinical trial at King’s College London will investigate the use of cannabidiol (CBD) – a compound found in …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
